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Objective: To assess the cost of congenital heart dis-
ease (CHD) and to assess whether practice pattern or price
was more responsible for variation.
Research Design and Setting: Data were collected
from Charleston, NC; Columbus, Ohio; Detroit, Mich;
Houston, Tex; Los Angeles, Calif; and New York, NY. The
CHD was first classified as to physiologic characteristics
and severity. For each type of CHD, the number of clinic
visits, hospitalizations, and years of medication use were
estimated.
Results: On the basis of actual charges, the "prices"
were calculated as follows, in 1992 dollars: for patients
from birth to 21 years: benign disease (19% of
patients), $3940; acyanotic disease (45%), $49 730;
cyanotic disease (36%), $102 084; and average for all
CHD categories, $59 877; for patients 22 to 40 years of
age (of whom 24% had resolved defects or were dead):
benign disease (19%), $3470; acyanotic disease (52%),
$12 981; cyanotic disease (29%), $39 187; and average
for all CHD, $18 773. The cost for the group from
birth to 21 years varied from $47 500 to $73 600,
accounting for 55% by practice (number of echocar-
diograms and cardiac catheterizations) and 45% by
price, although mortality was similar.
Conclusions: The treatment of CHD is comparatively
inexpensive, especially in adult survivors. The variation
in both practice and price bears further study, with com-
parisons to determine the most cost-effective strategies
for treating these patients.
(Arch Pediatr Adolesc Med. 1994;148:1039-1045)
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The population of chil¬dren and adults withchronic disease has in¬creased markedly in thelast decade because of im¬
proved survival·1"3 It has been estimated
that 6% of children have a chronic illness
(approximately 3.6 million in the United
States).4 If this population were concen¬
trated in one city, it would be the fourth
largest city in the United States. As this
group grows, concerns are appropriately
directed at the cost of their care for the fol¬
lowing reasons: (1) to budget appropri¬
ately for current and future programs to
pay for their health care, (2) to use these
statistics as a baseline for assessing fu¬
ture cost-benefit ratios for certain forms
of treatment, and (3) to assess the invest¬
ment by the health care system in these
children so that ways are found to opti¬
mize that investment when the children
become adults.
A major focus of cost analysis is to at¬
tempt to reduce present and future costs
by addressing the variation in pricing as
well as the variation in the practice of medi¬
cine. For exampie, if two institutions have
similar outcomes but one institution per¬
forms twice as many tests, this should pro¬
vide an objective basis for determination
of an appropriate level of testing to be re¬
imbursed.
Therefore, in this study, we sought
to assess both the cost and the variation
in pricing and practice for a chronic dis¬
ease among six geographically represen¬
tative centers in the United States. Con¬
genital heart disease was chosen as a
See Patients and Methods
on next page
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PATIENTS AND METHODS
CLASSIFICATION OF CONGENITAL
HEART DISEASE
Congenital heart disease was categorized by functional cri¬
teria rather than by single anatomic diagnosis. Six catego¬
ries for the ages of birth to 21 years were used: (1) benign
(no anticipated need for cardiac catheterization or surgery)(eg, small ventricular septal defect); (2) acyanotic congeni¬
tal heart disease with infant surgery, which required the pa¬
tient to undergo surgery within the first year of life (eg, com¬
plete atrioventricular septal defect); (3) acyanotic with later
surgery (beyond 1 year of age) (eg, simple coarctation of the
aorta); (4) acyanotic with intervention, in which a catheter
was used to treat congenital heart disease (eg, valvular pul¬
monary stenosis); (5) cyanotic, without the Fontan opera¬
tion (eg, tetralogy ofFallot); and (6) cyanotic, with the Fon¬
tan operation (eg, tricuspid atresia, with a procedure to direct
systemic venous inflow to the lungs).
Two age groups were examined: birth to 21 years (cor¬
responding to the duration of the majority of state funding
programs for children) and 22 to 40 years. The upper age limit
of40 years was chosen to estimate the onset ofsuperimposed
diseases, such as coronary artery disease. For the ages of 22
to 40 years, the following five categories were used: (1) be¬
nign; (2) postoperative, acyanotic; (3) postoperative, cyanotic
(tetralogy of Fallot); (4) postoperative, cyanotic (Mustard's
operation [atrial repair for transposition] or Fontan opera¬
tion); and (5) pulmonary vascular obstructive disease.
SUBCATEGORIES
For each category, subcategories were developed to re¬
flect ( 1 ) the timing with respect to intervention and (2) the
severity of the patient's course as would be described by
the numbers of procedures, hospitalizations, and clinic vis¬
its. For example, for the age group birth to 21 years, the
cyanotic, non-Fontan operation category (eg, tetralogy of
Fallot) had five subcategories. The first subclass incorpo¬
rated all patients for the first year of life, with the assump¬
tion that a typical patient would have a neonatal hospital
stay, an operation (either palliation or correction), and a
number of clinic visits. However, it was then assumed that
after the first year, patients would have different clinical
courses depending on their specific lesion and the results
of surgery. Physicians assigned typical clinical courses to
these subcategories (eg, "good") for the patients with good
results. The lists of categories and subcategories are shown
in Table 1 and Table 2.
CATEGORIZED SERVICES
The clinical course ofeach patient was described objectively
by seven services: (1) A routine clinic visit was defined as a
physician visit, with an electrocardiogram and a chest roent-
genogram. (2) A complex clinic visit was defined as a rou¬
tine clinic visit plus either an echocardiogram or a 24-hour
electrocardiogram (Hoher). (3) A medical hospitalization
was defined as admission for either diagnostic or medical
treatment. (4) A surgical hospitalization was defined as hos¬
pitalization for cardiac surgery and its recovery. (5) Inter-
ventional hospitalization was one in which the patient un¬
derwent cardiac catheterization with an interventional pro¬
cedure. (6) Pacemaker hospitalization was defined as the
implantation or changing of a pacemaker generator and/or
pacemaker leads. (7) The final category was the number of
years the patient was taking cardiac medication.
SERVICES AND CHARGES FROM SIX CENTERS
Six centers were chosen for their geographic and popula¬
tion variability: Charleston, SC, Columbus, Ohio, Detroit,
Mich, Houston, Tex, Los Angeles, Calif, and New York, NY.
The following data were obtained from each center: ( 1 )
The investigators were asked to estimate, on the basis of their
personal experience in that institution, the percentage of pa¬
tients who fell into each subcategory. Part of each subcat-
egory assignment also included a mortality for that subclass
over the period covered (either birth to 21 years or 22 to 40
years). (2) Each investigator then estimated the number of
clinic visits, hospitalizations, and years of medication use
for each of the subcategories. For example, ifan infant with
a small ventricular septal defect was seen twice in the first
year of life (one visit with an echocardiogram and one with¬
out) and then was followed up every 2 years to the age of
21 years, with every other visit (every fourth year) includ¬
ing an echocardiogram, the total would be six routine clinic
visits and six complex clinic visits. These data had to be es¬
timated (rather than obtained through chart review) for two
reasons: such detailed data were not available on patients
for the last 21 years and the practice ofpediatrie cardiology
has changed markedly during the last 21 years. The inves-
chronic disease that has a relatively high prevalence (al¬
most 1% of all births),5 that has broadly similar ap¬
proaches to treatment (ie, the majority of cyanotic in¬
fants will require some form of surgery), and that has
excellent survival to adulthood (85% to 90%).13 This
model could be applicable to other forms of chronic dis¬
ease in both children and adults as an approach to char¬
acterizing the various clinical courses in an objective form
and to costing of each outcome.
RESULTS
DISEASE CATEGORIES FOR BIRTH
TO 21 YEARS OF AGE
The disease categories, their estimated relative frequencies,
and mortality are shown in Table 1. The largest group was
the acyanotic category (45%), followed by cyanotic (36%)
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tigators were asked to proj ect how they would handle a child
in each subclass on the basis of current medical knowledge.
(3) Investigators provided data from each of their local in¬
stitutions on mean charges (physician fee and hospital charge)
for each of the types of clinic visit and hospitalization, in 1992
dollars. The medication prices were calculated for a 1-year
supply of digoxin and furosemide (liquid or tablet formu¬
lation appropriate to the age of the patient).
After the data on practice patternwere collected, thepooled
data were presented to each of the investigators in a modified
Delphi approach for possible change in the estimates.
STATISTICAL METHODS
Pooled Data
For each institution, a weighted average (by the percentage
of patients in each subcategory) was calculated for each of
the number of clinic visits, hospitalizations, and years of medi¬
cation. For example, in the disease category cyanotic, non-
Fontan operation, the number of services provided in the
first year was added to the weighted average of the four sub-
categories from 1 to 21 years of age for a total number of
services provided between birth and 21 years of age. The in¬
put data for that calculation are shown in Table 3.
For the age category birth to 21 years, data for each of
the six disease categories were averaged among the six in¬
stitutions. Similar calculations were made for the five dis¬
ease categories between 22 and 40 years of age. The output
data for these calculations are shown in Table 4.
For each disease category, the average number (among
the six institutions) of each of the services (eg, routine clinic
visit) was multiplied by the average charges to obtain total
charges by class (Table 5).
With the pooled data from the six institutions, the per¬
centage of patients estimated in each of the age groups in
the three major types of congenital heart disease (benign,
acyanotic, and cyanotic) and the charges estimated for each
of the three types were calculated (Table 6).
Estimation of Variation in Price and Practice
Among the Six Centers
The field of accounting has long dealt with variance in cost
resulting from price and volume variances. Our approach
was to generalize from the three standard cost accounting
relationships described below to accommodate multiple
modalities (volumes), prices, and sites.6 The purposes of
this analysis were to identify (1) the dollar amount of varia¬
tion in treatment costs of congenital heart disease across
six cities, (2) the causes (sources) ofvariation, and (3) the
proportion of total variation in costs that is attributable to
each of the sources. Three definitional relationships formed
the basis for this approach.
1. Price variance= (price for a service at a center—mean
price for that service for six centers) X frequency for that
service at that center.
2. Practice pattern variance=(frequency of a service at
a center—mean frequency for that service for six centers)
Xmean price for that service.
3. Cost variance=price variance + practice pattern
variance.
Since an overall course of treatment is composed of mul¬
tiple medical services, there will also be a "treatment pattern"
(a combination of choice and frequency of medical services,
ie, a composite of practice patterns) for each city and corre¬
spondingly a variation in treatment patterns and in total cost
of treatment. The cost of treatment in each city is determined
by combining prices of individual medical services in each city
with the treatment pattern for a given condition for that city.
If the treatment of congenital heart disease involved only
one medical service, then the variation in treatment cost across
different cities would result from the variation in the price of
that service and the variation in frequency of prescribing that
service (variation in practice pattern for that service). The analy¬
sis of variation in treatment costs could then be handled by
simply applying the three definitional relationships given above.
However, since the treatment of congenital heart disease in¬
volves more than one medical service, our approach to ana¬
lyzing cost variation must be generalized to deal with mul¬
tiple services and multiple prices, and the substantial offset¬
ting effects of variations in practice patterns and prices on
variations in total treatment costs.
Expected Lifetime
Expected lifetime was defined as the age by which 50% of
subjects would be expected to die. The following esti¬
mates of cumulative mortality were used for the normal US
population: 1% by age 21 years, 5% by age 40 years, and
50% by age 75 years. The expected lifetime for individuals
with congenital heart disease was calculated by adding the
normal US population data to the excess associated with
congenital heart disease.
and benign heart disease (19%). The overall mortality for
the group was 9%, thus giving an estimated 91% survival
to age 21 years for patients with congenital heart disease.
DISEASE CATEGORIES
FOR 22 TO 40 YEARS OF AGE
The disease categories and their relative frequencies are
shown in Table 2. Also shown is the statistic indicating
patients who were unavailable for follow-up or dead. For
the patients with benign disease, this implies unavailabil¬
ity for follow-up, whereas for those with acyanotic or cya¬
notic congenital heart disease, it implies death before the
age of 21 years. Because of the higher death rate in cya¬
notic patients and the large number of patients with be¬
nign heart disease assumed to be unavailable for follow-
up, the percentage of acyanotic patients over the age of
21 years is greater than the percentage less than 21 years.
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Mortality from 21 to 40 years of age was estimated at 2%
for acyanotic patients, 5% for cyanotic patients without
the Fontan operation, and 10% for those undergoing the
Mustard or Fontan operation.
The expected lifetimes were calculated to be 64.9
years for acyanotic patients, 49.0 years for cyanotic pa¬
tients, and 57.3 years for all patients.
VOLUME OF SERVICES FOR
CLINICAL PRACTICE
The volume of services for birth to 21 years of age is shown
in Table 4. The patients who had the Fontan operation
used the most services, followed by other cyanotic pa¬
tients and then acyanotic patients who underwent sur¬
gery in infancy. These were the three most intensive di-
Table 1. Disease Categories, Birth to 21 Years
Category % of Patients* % Mortality
Benignf
Acyanotic, infant surgery
Acyanotic, later surgery
Acyanotic, with intervention
Cyanotic, non-Fontan operation
Cyanotic, Fontan operation
19±3
19±3
14+3
12+5
24±3
12±3
0
12
4
2
11
25
*Mean±SD.
1/Vo intervention or medical treatment required.
Table 2. Disease Categories, Ages 22 to 40 Years
% No Longer Seen or
Category % of Patients* Dead by Age 21 y
Benign 12+3 53
Postoperative, acyanotic 52±2 13
Postoperative, tetralogy
of Fallot 13+2
Postoperative, Mustard
operation/Fontan
operation 20 ±4 25
Elsenmenger complex 3±1
*Mean±SD.
agnoses, followed by the other three in decreasing order:
acyanotic with later surgery, acyanotic with interven¬
tion, and benign. An example of the wide range of ser¬
vices provided depending on diagnosis is indicated by
total number of cfinic visits for the period from birth to
21 years: 34.6 in the cyanotic, Fontan operation group;
26.6 in the cyanotic, non-Fontan operation group; 22.1
in the acyanotic, infant surgery group; 14.8 in the acya¬
notic, later surgery group; 11.9 in the acyanotic, inter¬
vention group; and 8.3 in the benign group.
CHARGES
Mean charges are shown in Table 4. The charges for a
complex clinic visit (including an echocardiogram or 24-
hour Hoher monitoring) were 4.1 times the cost of a rou¬
tine clinic visit. The charges for surgical hospitalization
were 3.25 times the charges for an interventional hospi¬
talization.
Total Charges by Category
The total charges from birth to 21 years of age are shown
in Table 5. Surgical hospitalization accounted for the larg¬
est amount of the charges; the two next highest charges
were complex clinic visits and medication.
Charges by Lesion
The overall charges estimated by type of lesion are shown
in Table 6. Of the charges that occurred between birth
and 40 years of age, 74% occurred in the first 21 years of
life. Of the overall charges, patients with cyanotic con¬
genital heart disease accounted for 67% (atthough they
only composed 36% of the patients), patients with acya¬
notic congenital heart disease accounted for 30% (al¬
though they were approximately 50% of the patient popu¬
lation) , and patients with benign congenital heart disease
accounted for 3% of the charges (approximately 14% of
the patients). Thus, charges for patients with congenital
heart disease averaged $59 877 between birth and 21 years
of age and $21 274 between 22 and 40 years of age, for a
total of $81 151 per patient.
Table 3. Use of Services in the Cyanotic, Non-Fontan Operation Group, Birth to 21 Years
Subcategory,
Age and Results
Clinic Visit*
%of
Age Group
Hospitalization*
 -
Routine Complex Pacemaker Medical Surgical Pacemaker
Years
Taking
Medication
Birth-1 y
1-21 y, good
1-21 y, moderate
1-21 y, poor
1-21 y, pacemaker
100
26
43
18
5
2.3
5.2
7.8
5.8
1.7
3.3
7.0
13.7
25.8
10.0
0
0
0
0
24.5
1.1
0
0.5
1.6
0.5
1.1
0
0.5
1.6
0.7
1.1
0
0.5
1.6
0.7
1.0
0.2
13.0
19.0
10.0
"Average number of services used during the period stated (eg, between birth and 1 year of age, the average patient had 2.3 routine clinic visits).
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Table 4. Volume and Cost of Services by Disease Category, Birth to 21 Years
Clinic Visit Hospitalization
Routine Complex Pacemaker Medical Surgical Intervention Pacemaker Medication
Cost,$ 164 681 950 5632 35857 11042
Disease category, No.
of services
Benign 4.4 3.9 0 0.4 0 0
Acyanotic, infant
surgery 9.0 11.0 1.2 2.0 1.2 0
Acyanotic, later
surgery 4.9 9.2 0.7 0.1 1.0 0
Acyanotic, intervention 3.7 8.2 0 0 0 1.1
Cyanotic, non-Fontan
operation 8.6 16.6 1.4 2.3 1.6 0
Cyanotic, Fontan
operation 9.4 24.0 1.2 1.9 2.2 0
18250
0
0.2
0.1
0
0.2
0.2
650
0
8.6
0.4
0
0.5
13.8
Table 5. Total Charges by Disease Category, Birth to 21 Years
Charge, $
Category
Clinic Visit Hospitalization
Routine Complex Pacemaker Medical Surgical Intervention Pacemaker Medication Total
Benign 721 2656 0 563 0 0 0 0 3940
Acyanotic, infant surgery 1474 8104 1140 11262 41953 0 2920 5590 72443
Acyanotic, later surgery 803 6265 703 450 35 857 0 1825 260 46163
Acyanotic, intervention 606 5584 0 0 0 11925 0 0 18115
Cyanotic, non-Fontan operation 1409 11305 1330 12 951 56 295 0 3468 6175 92 933
Cyanotic, Fontan operation 1540 16344 1140 10699 78527 0 2920 8970 120140
Interinstitutional Variation
The interinstitutional variations between birth and 21
years of age are shown in Table  and Table 8. Over¬
all, the minimum charge for an average patient was
$47 515 and the maximum was $73 606, a 55% overall
variation. This $26 091 variation between the lowest and
the highest was accounted for both by variations in prac¬
tice pattern (volume), which accounted for 55% of the
variation, and by price, which accounted for 45% of the
variation. The greatest variation in practice was in inter¬
ventional hospitalizations, medical hospitalizations, and
complex clinic visits (echocardiograms); the least varia¬
tion was in surgical hospitalization. In price, the great¬
est variation was in medical hospitalization and the least
was in the cost of medicine per year.
Mortality and Charges
In Table 8 the mortality from birth to 21 years of age for
each institution is shown along with the charges for that
institution. There was essentially no relationship be¬
tween the mortality and the charges. Since the charges
were calculated and averaged only for live patients, no
Table 6. Charges by Lesion
Birth-21 y 22-40 y
-1  -1 Total,$ % $ $
Benign 19 3940 12 3470 7410
Acyanotic 45 49730 52 12981 62711
Cyanotic 36 102084 36 39187 141271
Mean
...
59 877
...
21274 81151
relationship should be expected between mortality and
charges. Therefore, these data can be used as a crude es¬
timate of the benefit-cost ratio.
COMMENT
COST
In this study, we estimated that 91% of patients with con¬
genital heart disease survive to adulthood. A figure of 90%
survival to adulthood has been confirmed in other stud¬
ies.1"3 According to the data on natural survival patterns in
congenital heart disease, the expected lifetime for patients
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Table 7. Institutional Variation in Clinics and Hospitalizations, Birth to 21 Years
Institution
Routine clinic visit
No. of services 6.2 5.5 10.1 7.4 7.0 6.4
Charge per service, $ 225 150 233 190 175 210
Total, $ 1395 825 2353 1406 1225 1344
Complex clinic visit
No. of services 16.9 8 9.5 12.9 16 16.3
Charge per service, $ 625 1000 643 700 425 642
Total, $ 10563 8000 6109 9030 6800 10465
Medical hospitalization
No. of services 1.28 0.55 1.28 1.0 1.23 1.75
Charge per service, $ 6350 3500 6350 7000 4500 6090
Total, $ 8128 1925 8128 7000 5535 10658
Surgical hospitalization
No. of services 1.01 0.94 1.01 0.88 0.96 1.18
Charge per service, $ 33571 39203 33571 45000 26956 36 844
Total, $ 33907 36851 33907 39600 25878 43476
Intervention hospitalization
No. of services 0.13 0.13 0.10 0.13 0.20 0.05
Charge per service, $ 12500 9000 10750 10000 12 500 11500
Total, $ 1625 1170 1075 1300 2500 575
Table 8. Institutional Variation in Mortality
and Charges, Birth to 40 Years
Institution
 
A  
Mortality, % 8 8 5 4 8 7
Charges, $ 63283 57 071 59187 62 346 47 515 73606
with acyanotic heart disease is a minimum of 19.5 years
(because of possible underdetection), and that for unop-
erated-on cyanotic heart disease is 1.4 years.7 According
to the estimates from this study, with optimal medical and
surgical treatment, the expected lifetime for patients with
acyanotic heart disease is 64.9 years, and for those with cya¬
notic heart disease, 46.0 years. These numbers can then be
compared with data for patients with untreated heart dis¬
ease. With the use of the crude measure of years of im¬
proved mortality per dollar spent, the cost-benefit ratio for
all acyanotic congenital heart disease (including benign)
is $46 914/45 years=$1029 per life year, and that for cya¬
notic congenital heart disease is $ 141 271/44.6 years=$3168
per life year. For comparison, the data published by
Kuppermann et al8 were adjusted to 1991 constant dol¬
lars. Our data for congenital heart disease compare ex¬
tremely favorably with those of Kuppermann et al (ad¬justed for 1991 constant dollars): neonatal intensive care
(1000- to 1500-g infants), $7040 per life year; neonatal in¬
tensive care (500- to 999-g infants), $49 664; and coro¬
nary artery bypass surgery for three-vessel disease, $92 016.
Comparative costs of pediatrie diseases. CF indicates cystic fibrosis; MD,
muscular dystrophy; and NB, newborn. Data from the Texas Chronically III
and Disabled Children's Program.9
COST-BENEFIT COMPARISON
WITH OTHER DISEASES
The results of the present study indicate that charges for
congenital heart disease averaged $2851 per year between
birth and 21 years of age and $1120 per year between the
ages of22 and 40 years. In an attempt to validate these num¬
bers, we compared them with actual payment data from the
Texas Chronically 111 and Disabled Children's (CIDC) Pro¬
gram for 1991,9 in which annual expenditures per patient
aged 0 to 21 years were $ 1854. The CIDC Program pays ap¬
proximately 70% of charges, thus allowing for calculated
charges of $2649. This agrees closely with our estimate of
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$2851 for charges. In the Figure, the CIDC Program ex¬
penditures for children aged 0 to 21 years with heart dis¬
ease are graphed and compared with expenditures made
by the CIDC Program for other chronic diseases in child¬
hood as well as newborn screening. The estimate of the cost
per patient per year for adult congenital heart disease on
the basis ofour study is also included. Therefore, compared
with the common childhood diseases, congenital heart dis¬
ease is among the least expensive. For example, hemophilia
costs $ 11313 per year (6.1 times the cost ofcongenital heart
disease), and cystic fibrosis costs $6642 per year (3.6 times
the cost of congenital heart disease). One weakness of the
present study is that the data are based on estimates ofprac¬
tice rather than on actual data. It is not possible to obtain
the actual data, since records of each test ordered at each
visit for 40 years are not available. Therefore, our method
provides the best possible estimates available at present.
VARIATION IN PRACTICE AND PRICE
This study demonstrated a 55% variation among six cen¬
ters in the charges for congenital heart disease between
birth and 21 years of age. This study also demonstrated
that this variation in charges was not related to outcome
as measured by mortality, ft is well recognized that there
are other important outcomes, including morbidity and
patient satisfaction, but these were not assessed in the
present study. Since no benefit of spending more on the
patient was demonstrated with the use of mortality as the
only outcome, future studies should assess other out¬
comes. This study demonstrated that approximately half
of the variation was in practice pattern. As has been well
described by Fowler et al10 and Wennberg,11 the varia¬
tion in practice pattern is not necessarily based on for¬
mal estimation of outcome.
On the basis of this study, it appears that the great¬
est variation was in the use of complex clinic visits and
cardiac catheterization. It therefore appears appropriate
to examine prospectively the necessity for follow-up echo-
cardiography and follow-up cardiac catheterization af¬
ter the initial diagnosis in patients with congenital heart
disease. Since there was a 55% variation in overall charges,
and half of that was accounted for by practice pattern, it
should be possible to approach approximately a 30% re¬
duction (0.55X0.50) in overall charges for congenital
heart disease by having a practice pattern more like that
of hospitai  in Table 7 and less like that of hospital E.
Similarly, it may be possible to reduce overall charges
by decreasing the variation in prices. This would only
hold true if, as demonstrated, vafues for outcomes were
the same at the lowest resource utilization. The cur¬
rently allowed Medicare variation among the cities rep-
resented in this study was 9%.IZ On this basis alone, it is
likely that the price variability should be significantly less
in the future than that reflected in the present study.
A MODEL FOR CHRONIC DISEASE
This study has demonstrated that a common chronic
disease of childhood can be classified into a number of
types and, within each type, subclassified by severity of
course. By means of a multicenter approach, practice
variation can be assessed and related to outcome. The
degree to which practice variation does not relate to
outcome provides the opportunity to reduce the varia¬
tion and produce objective guidelines with utilization of
less services than currently provided. It is possible that,
when presented with this type of objective data, physi¬
cians will respond in a positive way to make the practice
of medicine more appropriate and to reduce the cost of
medical care.
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